Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Indapta Therapeutics is using a subset of natural killer cells found in healthy donors to supercharge monoclonal antibodies to fight cancer and autoimmune disease.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
24,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
209,00 € per year
only 17,42 € per issue
Buy this article
Purchase on Springer LinkInstant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Log in
Learn about institutional subscriptions
Read our FAQs
Contact customer support
Author information
Authors and Affiliations
Berlin, Germany
Iris Marchal
About this article
Cite this article
Marchal, I. Editor’s pick: Indapta Therapeutics.
Nat Biotechnol (2024). https://doi.org/10.1038/s41587-024-02334-9
Download citation
Published: 22 July 2024
DOI: https://doi.org/10.1038/s41587-024-02334-9
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : Nature.com – https://www.nature.com/articles/s41587-024-02334-9
